Amgen shares climb after judge upholds Repatha patents
A ruling in a patent law case regarding a new anti-cholesterol drug involving Thousand Oaks biotech giant Amgen has skyrocketed Amgen shares. Amgen filed a patent infringement lawsuit against Sanofi and Regeneron in the U.S. District Court of Delaware in October 2014 to block the development and sale of the drug Praluent, which was developed Read More →
Read More →
Corporate tax cut could fuel biotech mergers, acquisitions
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen alumni start their own biotech companies
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen wins one, loses one in biosimilar battle
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Thousand Oaks city manager’s firing won’t hinder economy
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Ceres faces lawsuit over sale to Land ‘O Lakes
Thousand Oaks-based ag-biotech company Ceres Inc. is facing a lawsuit from shareholders angry about the company’s June 17 sale to Minneapolis-based Land ‘O Lakes. In the lawsuit, which was filed in state court in Los Angeles on July 5, three shareholders allege the company unfairly sold the company to Land ‘O Lakes for $17.6 million. Read More →
Read More →Stellar Biotechnologies uses limpets to develop medicine
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Sponsored content:
2015-2016 Giving Guide
